Cargando…

Diagnosis and Treatment of Rheumatic Adverse Events Related to Immune Checkpoint Inhibitors

Immune checkpoint inhibitors (ICIs) have completely changed the treatment of cancer, and they also can cause multiple organ immune-related adverse reactions (irAEs). Among them, rheumatic irAE is less common, mainly including inflammatory arthritis, rheumatic myalgia/giant cell arteritis, inflammato...

Descripción completa

Detalles Bibliográficos
Autores principales: Xiao, Yan, Zeng, Lin, Shen, Qinglin, Zhou, Zhiyong, Mao, Zhifang, Wang, Qin, Zhang, Xiquan, Li, Yingliang, Yao, Weirong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Hindawi 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7424376/
https://www.ncbi.nlm.nih.gov/pubmed/32832568
http://dx.doi.org/10.1155/2020/2640273
Descripción
Sumario:Immune checkpoint inhibitors (ICIs) have completely changed the treatment of cancer, and they also can cause multiple organ immune-related adverse reactions (irAEs). Among them, rheumatic irAE is less common, mainly including inflammatory arthritis, rheumatic myalgia/giant cell arteritis, inflammatory myopathy, and Sjogren's syndrome. For oncologists, rheumatism is a relatively new field, and early diagnosis and treatment is very important, and we need to work closely with experienced rheumatologists. In this review, we focused on the incidence, clinical characteristics, and treatment strategies of rheumatic irAE.